Herceptin
Generic name: Trastuzumab
Drug class:
HER2 inhibitors
Usage of Herceptin
Herceptin is a cancer medicine that interferes with the growth and spread of cancer cells in the body. Herceptin is used to treat certain types of breast cancer or stomach cancer. Other cancer medicines are sometimes used in combination with Herceptin.
Herceptin is sometimes used when the cancer has spread to other parts of the body (metastatic).
Herceptin side effects
Get emergency medical help if you have signs of an allergic reaction to Herceptin: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Some side effects may occur during the injection, or in the days afterward. Tell your caregiver right away if you feel dizzy, nauseated, itchy, light-headed, weak, short of breath, or if you have a headache, fever, chills, or chest pain.
Call your doctor at once if you have:
Your cancer treatments may be delayed or permanently discontinued if you have certain side effects.
Common Herceptin side effects may include:
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Before taking Herceptin
You should not be treated with Herceptin if you are allergic to trastuzumab.
To make sure Herceptin is safe for you, tell your doctor if you have ever had:
Trastuzumab can cause heart failure, especially if you have heart disease or if you are also receiving certain other cancer medicines (such as daunorubicin, doxorubicin, Epirubicin, or idarubicin).
You may need to have a negative pregnancy test before starting this treatment.
Do not use Herceptin if you are pregnant. This medicine can cause injury or death to the unborn baby. Use effective birth control to prevent pregnancy while you are using this medicine and for at least 7 months after your last dose. Tell your doctor if you become pregnant during treatment.
If you become pregnant while using this medicine or within 7 months after you stop, your name may be listed on a pregnancy registry to track the effects of trastuzumab on the baby.
It may not be safe to breastfeed while using this medicine and for up to 7 months after your last dose. Ask your doctor about any risk.
Relate drugs
- Ado-trastuzumab emtansine
- Enhertu
- Fam-trastuzumab deruxtecan
- Fam-trastuzumab deruxtecan-nxki
- Herceptin
- Herceptin Hylecta
- Herzuma
- Herzuma (Trastuzumab Intravenous)
- Herzuma (Trastuzumab-pkrb Intravenous)
- Hyaluronidase and trastuzumab
- Hyaluronidase, pertuzumab, and trastuzumab
- Kadcyla
- Margenza
- Margetuximab
- Margetuximab-cmkb
- Ogivri
- Ogivri (Trastuzumab Intravenous)
- Ogivri (Trastuzumab-dkst Intravenous)
- Ontruzant
- Ontruzant (Trastuzumab Intravenous)
- Ontruzant (Trastuzumab-dttb Intravenous)
- Perjeta
- Pertuzumab
- Pertuzumab, trastuzumab, and hyaluronidase-zzxf
- Phesgo
- Trastuzumab
- Trastuzumab and hyaluronidase-oysk
- Trastuzumab-anns
- Trastuzumab-dkst
- Trastuzumab-dttb
- Trastuzumab-pkrb
- Trazimera
- Tucatinib
- Tukysa
How to use Herceptin
Usual Adult Dose of Herceptin for Breast Cancer:
For use in the treatment of metastatic breast cancer: Administer trastuzumab, alone or in combination with paclitaxel. Initial dose: 4 mg/kg IV infusion over 90 minutes Subsequent therapy: 2 mg/kg IV infusion over 30 minutes once weekly until disease progression
Usual Adult Dose of Herceptin for Breast Cancer -- Adjuvant:
Administer according to one of the following doses and schedules: 1) Initiate trastuzumab during and following paclitaxel, docetaxel, or docetaxel/Carboplatin: Initial dose: 4 mg/kg IV infusion over 90 minutes then 2 mg/kg IV infusion over 30 minutes weekly during chemotherapy for the first 12 weeks (paclitaxel or docetaxel) or 18 weeks (docetaxel/carboplatin). Subsequent therapy: one week after the last weekly dose of trastuzumab, give trastuzumab as 6 mg/kg IV infusion over 30 to 90 minutes every 3 weeks for a total of 52 weeks of therapy. or 2) Initiate trastuzumab as a single agent within 3 weeks following completion of all chemotherapy. Initial dose: 8 mg/kg IV infusion over 90 minutes Subsequent therapy: 6 mg/kg IV infusion over 30 to 90 minutes every 3 weeks for a total of 17 doses (52 weeks of therapy)
Usual Adult Dose of Herceptin for Esophageal Carcinoma:
For use in the treatment of metastatic gastric or gastroesophageal junction adenocarcinoma: Administer trastuzumab in combination with cisplatin and Capecitabine or 5-fluorouracil. Initial dose: 8 mg/kg IV infusion over 90 minutes Subsequent therapy: 6 mg/kg IV infusion over 30 to 90 minutes every 3 weeks until disease progression
Usual Adult Dose of Herceptin for Gastric Cancer:
For use in the treatment of metastatic gastric or gastroesophageal junction adenocarcinoma: Administer trastuzumab in combination with cisplatin and capecitabine or 5-fluorouracil. Initial dose: 8 mg/kg IV infusion over 90 minutes Subsequent therapy: 6 mg/kg IV infusion over 30 to 90 minutes every 3 weeks until disease progression
Warnings
Do not use Herceptin if you are pregnant. It could harm the unborn baby. Avoid becoming pregnant for at least 7 months after your last dose of trastuzumab. Use effective birth control, and tell your doctor if you become pregnant during treatment.
Herceptin can cause heart failure, especially if you have heart disease or if you are also receiving certain other cancer medicines.
Some side effects may occur during the injection. Tell your caregivers if you feel dizzy, nauseated, light-headed, weak, short of breath, or if you have a headache, fever, or chills.
What other drugs will affect Herceptin
Other drugs may interact with trastuzumab, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using.
Trastuzumab can have long lasting effects on your heart, especially if you receive other cancer medicines. For at least 7 months after your last dose of Herceptin, tell any doctor who treats you that you have used this medicine.
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions